Abelacimab for prevention of venous thromboembolism after knee replacement. NEJM 2021

Cardio-Ed

English - July 26, 2021 10:30 - 5 minutes - 4.16 MB - ★★★★★ - 1 rating
Medicine Health & Fitness cardiology interventional cardiology echocardiography clinical trials medicine structural heart disease heart failure arrhythmia myocardial infarction cardiomyopathy Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: ADAPTABLE trial. Aspirin doses for secondary prevention. NEJM 2021

Next Episode: Device related thrombosis after LA appendage occlusion.

#Abelacimab for #VenousThromboembolism prevention after #TotalKneeReplacement, published in July 2021 edition of #NEJM.

#Abelacimab is #MonoclonalAntibody against #Factor XI, a key component of #intrinsicCoagulationPathway. It has been used in prevention of Venous Thromboembolism after Total Knee Replacement and compared to #Enoxaparin.
In this study published in #NEJM or the #NewEnglandJournalOfMedicine Abelacimab has been used in 4 doses and its safety and efficacy has been studied. Abelacimab blocks the intrinsic clotting pathways and may be a useful drug in our armamentarium of venous thromboembolism prevention after orthopaedic surgeries like total knee replacement.
To know about Abelacimab, intrinsic coagulation pathway inhibition and venous thromboembolism prevention after Total knee replacement watch this video.
Follow #Cardio-Ed for more such content on recent advances, recent guidelines and recent articles in the field of cardiology.

https://youtube.com/channel/UCVxInTblTpoy-THMuSxNyvw

-~-~~-~~~-~~-~-
Please watch: "ADAPTABLE trial. Aspirin dose for secondary prevention. "
https://www.youtube.com/watch?v=94lhXi3nQUs
-~-~~-~~~-~~-~-